Orforglipron vs 5-Amino-1MQ
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: LY3502970, OWL833
An oral non-peptide GLP-1 receptor agonist. FDA approved April 1, 2026 under the brand name Foundayo — the first daily oral GLP-1 pill for weight loss. Distribution began April 6, 2026. FDA subsequently requested additional post-approval safety data.
Also: 5-amino-1-methylquinolinium, NNMT Inhibitor
A selective NNMT (nicotinamide N-methyltransferase) inhibitor that enhances cellular energy metabolism. Not a peptide but a small molecule research compound commonly used alongside peptides for fat loss and metabolic support.
Key Comparison Insights
- Orforglipron is FDA approved, while 5-Amino-1MQ remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Orforglipron has stronger research evidence (Human Trials) compared to 5-Amino-1MQ (Animal Studies).
Detailed Comparison
| Attribute | Orforglipron | 5-Amino-1MQ |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Orforglipron is a small molecule that activates GLP-1 receptors similarly to peptide GLP-1 agonists. Being a non-peptide allows oral bioavailability without the special formulation needed for oral semaglutide. | 5-Amino-1MQ inhibits NNMT, an enzyme that regulates NAD+ and SAM (S-adenosyl methionine) levels. By blocking NNMT, it increases NAD+ availability, enhancing mitochondrial function, promoting fat oxidation, and supporting cellular energy metabolism. It does not affect appetite or food intake. |
| Common Dosing | Limited community data available See research protocols | 50-75 mg daily Once daily, morning |
| Administration | Oral tablet daily | Subcutaneous injection or oral |
| Typical Duration | Long-term use expected | 4-6 weeks (cycling recommended) |
| Best Time to Take | Before bed or morning (fasted) | Morning, fasted |
Possible Side Effects May vary by individual |
|
|
| Research Summary | ATTAIN-1 Phase 3 results showed significant weight loss. ATTAIN-MAINTAIN showed it helps maintain weight after injectable GLP-1 treatment. NDA submitted late 2025. Selected for FDA National Priority Voucher program but review was delayed to April 2026. FDA approved Foundayo (orforglipron) on April 1, 2026 under the National Priority Voucher Program — the fastest new molecular entity approval since 2002. It is the first oral non-peptide GLP-1 receptor agonist approved for chronic weight management. | Mouse studies showed over 30% decrease in adipocyte size and 40% decrease in adipocyte volume. Treated mice had 30% lower total cholesterol. No significant impact on food intake or adverse effects observed. Human clinical data remains limited. |
Frequently Asked Questions: Orforglipron vs 5-Amino-1MQ
What is the difference between Orforglipron and 5-Amino-1MQ?
Orforglipron is a weight loss peptide that an oral non-peptide glp-1 receptor agonist. fda approved april 1, 2026 under the brand name foundayo — the first daily oral glp-1 pill for weight loss. distribution began april 6, 2026. fda subsequently requested additional post-approval safety data. 5-Amino-1MQ is a weight loss peptide that a selective nnmt (nicotinamide n-methyltransferase) inhibitor that enhances cellular energy metabolism. not a peptide but a small molecule research compound commonly used alongside peptides for fat loss and metabolic support. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Orforglipron or 5-Amino-1MQ?
Neither is universally "better" - the choice depends on your specific goals. Orforglipron is typically used for weight loss purposes, while 5-Amino-1MQ is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Orforglipron and 5-Amino-1MQ be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Orforglipron and 5-Amino-1MQ together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.